Controversies in the management of gastrointestinal stromal tumors

Yip, Desmond, Zalcberg, John, Ackland, Stephen, Barbour, Andrew P., Desai, Jayesh, Fox, Stephen, Kotasek, Dusan, McArthur, Grant and Smithers, B. Mark (2014) Controversies in the management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 10 3: 216-227. doi:10.1111/ajco.12187


Author Yip, Desmond
Zalcberg, John
Ackland, Stephen
Barbour, Andrew P.
Desai, Jayesh
Fox, Stephen
Kotasek, Dusan
McArthur, Grant
Smithers, B. Mark
Title Controversies in the management of gastrointestinal stromal tumors
Journal name Asia-Pacific Journal of Clinical Oncology   Check publisher's open access policy
ISSN 1743-7563
1743-7555
Publication date 2014-09-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/ajco.12187
Open Access Status DOI
Volume 10
Issue 3
Start page 216
End page 227
Total pages 12
Place of publication West Sussex United Kingdom
Publisher Blackwell Publishing
Collection year 2015
Language eng
Subject 2730 Oncology
Formatted abstract
Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primary tumors. The Consensus approaches to best practice management of gastrointestinal stromal tumors, published in this journal in 2008, provided guidance for the management of GIST to both clinicians and regulatory authorities. Since then, clinical trials have demonstrated the benefit of adjuvant imatinib in high-risk patients, and mature data from advanced GIST studies suggest that a small but significant proportion of patients with advanced disease can achieve long-term benefit with ongoing imatinib treatment. Other evolving management strategies include the controversial use of palliative or debulking surgery to improve outcomes in advanced GIST and the development of promising new multikinase inhibitors, such as regorafenib, which has established benefit in the third-line setting. This review provides an update of recent developments in GIST management and discusses new controversies that these advances have generated.
Keyword Adjuvant
Gastrointestinal stromal tumor
Imatinib
Molecular target therapy
Risk stratification
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2015 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 20 Sep 2014, 04:30:34 EST by System User on behalf of Surgery - Princess Alexandra Hospital